Brands
YSTV
Discover
Events
Newsletter
More

Follow Us

twitterfacebookinstagramyoutube
Yourstory
search

Brands

Resources

Stories

General

In-Depth

Announcement

Reports

News

Funding

Startup Sectors

Women in tech

Sportstech

Agritech

E-Commerce

Education

Lifestyle

Entertainment

Art & Culture

Travel & Leisure

Curtain Raiser

Wine and Food

Videos

ADVERTISEMENT
Advertise with us

Investor Neuberger Berman slashes valuation in PharmEasy, Pine Labs

Investors have recently cut valuations in several Indian unicorns, including BYJU'S, Swiggy, Ola, and others.

Investor Neuberger Berman slashes valuation in PharmEasy, Pine Labs

Friday May 12, 2023 , 2 min Read

US investment firm Neuberger Berman has cut the valuation of its stake in both Api Holdings Limited, the parent company of Pharmeasy, and fintech giant Pine Labs.

PharmEasy and Pine Labs follow the likes of Ola, BYJU'S, Oyo, and Swiggy whose investors have also recently written down their valuations.

As of February 28, 2023, Neuberger Berman cut the valuation of Pine Labs to $3.1 billion from $5 billion, and PharmEasy's to $4.4 billion from $5.6 billion (almost a 21% decline), as per a regulatory filing with the Securities and Exchanges Commission in the US.

Pine Labs was last valued at over $5 billion after it closed a $150 million funding round from Alpha Wave Global, while PharmEasy was valued at $5.6 billion in its latest round where it raised $350 million in a pre-IPO fundraise.

In a regulatory filing in November last year, API Holdings said it intended to withdraw its draft red herring prospectus (DRHP) due to volatile market conditions.

Invesco, which recently devalued its stake in Swiggy, maintained Pine Labs' valuation.

How to do the Relative Valuation of Stocks? Basics of Stock Valuation
Also Read
Invesco cuts Swiggy's valuation to $5.5B amid volatility: Report

Temasek-backed PharmEasy has been struggling to raise funds despite cutting its workforce by around 40%, according to a DealStreetAsia report.

However, a Mint report, citing two people familiar with the matter, said PharmEasy has been turning things around for itself and became cash flow positive in April.

YourStory was unable to independently verify these reports.

Investors which recently cut valuations on Indian startups include the likes of Vanguard, SoftBank, Blackrock, and Invesco, among others.

API Holdings Ltd, the parent company of Pharmeasy, reported a net loss of Rs 3,992 crore for FY22 against Rs 641 crore in FY21 (2020-21), as per RoC filings with the Ministry of Corporate Affairs.


Edited by Akanksha Sarma